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Summary This short review summarizes the most
relevant data on colorectal liver metastases (CLM)
presented at the 2016 Annual Meeting of the Amer-
ican Society of Clinical Oncology (ASCO). For this
update, congress abstracts were grouped into three
clinically relevant scenarios: CLM that are deemed
upfront resectable, borderline resectable, and pri-
marily unresectable. According to a large registry
study, small, upfront resectable, solitary CLM should
be resected using a parenchymal sparing technique.
A prospective noninterventional study suggested that
chemotherapy plus the anti-VEGF (vascular endothe-
lial growth factor) antibody bevacizumab is effective
and well tolerated in patients with borderline re-
sectable CLM. In the setting of CLM deemed initially
unresectable, a phase 2 study reported superior out-
comes in terms of liver metastases resection rates
as well as overall survival (OS) in patients receiving
a chemotherapy triplet (FOLFIRINOX) plus a targeted
agent as compared to FOLFIRI or FOLFOX4 with the
same targeted therapy. Finally, a study suggested that
tailoring first-line chemotherapy according to TYMS-
3’UTR and ERCC1-118 polymorphism status results
in higher response rates and longer progression-free
survival (PFS) as well as OS.
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Review
In patients presenting with colorectal cancer liver
metastases (CLM), three clinical scenarios can be
distinguished: CLM that are deemed upfront re-
sectable, borderline resectable lesions, and initially
unresectable metastases that could be amendable to
curative resection in patients responding to induction
chemotherapy. The term “borderline resectable” is
commonly defined as metastases potentially amend-
able to curative resection but surgery of these lesions
is regarded technically and/or biologically more chal-
lenging than in upfront resectable CLM.
At the 2016 ASCO Annual Meeting, one abstract was
presented on the treatment of upfront resectable CLM
[1]. This study evaluated surgical as well as long-term
outcomes in patients with solitary small metastases
in the right liver who underwent either parenchy-
mal-preserving hepatectomy (PH) or anatomical right
hepatectomy (RH). Data were extracted from a large
registry (LiverMetSurvey) including 21,072 resections
performed between 2000 and 2015. A total num-
ber of 1720 patients met the inclusion criteria for
this analysis; of these, 1478 (86%) were treated with
PH, while 242 (14%) underwent RH. Patients in the
RH group had larger metastases, a higher percent-
age of initially unresectable disease, a lower rate of
laparoscopic resections and fewer patients received
postoperative chemotherapy as compared to the PH
group. Not surprisingly, PH was superior in terms of
number of blood transfusions required, duration of
in-hospital stay, rate of major complications as well as
90-day mortality rate while repeat hepatectomy was
less frequently performed after RH. Despite adverse
clinical features as outlined, there was no difference
in recurrence-free survival, time to last unresectable
recurrence, and OS between the two groups. When
patients with liver-only recurrences, however, were
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analyzed separately, time to last unresectable recur-
rence and OS was significantly longer in the PH group.
In a multivariate model, nodal status (RR 0.47; 95%
CI 0.23–0.95), CEA levels <15 ng/ml (RR 1.85; 95% CI
1.01–3.37), and PH (RR 3.7; 95% CI 1.77–7.72) were
significantly associated with superior 5-year OS. Al-
though these data were extracted from a registry and
this is not a randomized study, this study suggests
that PH should be regarded as a standard-of-care for
solitary small CLM.
Patients with borderline resectable metastases were
included into a multicenter, prospective noninterven-
tional study [2]. Patients received first line chemother-
apy (mostly FOLFOX or FOLFIRI) in combination
with bevacizumab, a humanized monoclonal anti-
body targeting VEGF. A total number of 218 patients
were included with 205 evaluable for outcome anal-
ysis. The primary objective was the rate of patients
without detectable metastatic disease (no evidence
of disease; NED) with or without secondary resec-
tion. Overall, 86% of patients had liver-only disease,
and 104 patients (51%) were resected after first-line
chemotherapy. NED was achieved in 92 patients (48%;
88 with surgery and 4 with chemotherapy alone).
Progression-free survival (PFS) was 15.7 months in
patients with NED as compared to 11.5 months in
patients without; OS at 36 months was 77% and 52%,
respectively. Therefore, this real-life study suggests
that chemotherapy plus bevacizumab is an effective
and well-tolerated treatment option in patients with
borderline resectable CLM.
In the setting of patients with CLM deemed ini-
tially as unresectable, the most relevant study was
a phase 2 trial evaluating different chemotherapy
backbones for induction therapy [3]. In all, 256 pa-
tients were randomized to receive a chemotherapy
doublet (either FOLFIRI or FOLFOX4, n = 126) or
triplet (FOLFIRINOX, n = 136) in combination with
either bevacizumab or cetuximab according to their
respective kRAS mutations status. The main objective
of the trial was the resection rate in both groups; of
note, due to the phase II design and stratification to
either bevacizumab or cetuximab patient subgroups
were rather small.
Triplet chemotherapy increased resection rates
from 45.2 to 56.9%(p = 0.062) and the combination
of chemotherapy with cetuximab yielded numerically
higher resection rates as compared to bevacizumab
(55.6% versus 44.7%; p = 0.087). Severe adverse events
were not significantly different between groups. Im-
portantly, median OS was significantly longer in pa-
tients receiving FOLFIRINOX (not reached versus
36 months, respectively; p = 0.048). The authors
therefore concluded that the combination of FOLFIRI-
NOX with targeted therapy was associated with better
OS and liver metastases resection rates than either
FOLFIRI or FOLFOX4 with targeted therapy.
High response and conversion rates (secondary
endpoints) were also described in a study that in-
vestigated modified FOLFOXIRI plus cetuximab fol-
lowed by cetuximab or bevacizumab maintenance
[4] although neither arm met the predefined primary
endpoint.
Another abstract dealt with the pharmacogenetic
selection of chemotherapy in unresectable CLM [5].
The design of this phase 2 study was based on ear-
lier results suggesting that patients harboring TYMS-
3’UTR +6 bp/+6 bp and ERCC1–118C/T or C/C geno-
types may derive greater benefit from capecitabine as
compared to 5-fluorouracil (FU) as part of an oxali-
platin-based first-line regimen. Overall, 180 patients
were randomized to a control arm (60 patients receiv-
ing XELOX plus bevacizumab) and an experimental
arm (120 patients receiving bevacizumab plus FUOX,
XELOX, FUIRI, or XELIRI based upon their pharma-
cogenetic profile). The combined rates of complete
and partial response were 48% in the control group
and 65% in the experimental group (p = 0.04). In to-
tal, 37 patients were converted to resectable status of
liver metastases, the R0 surgery rate was 43% (7/16) in
the control arm and 86% (18/21) in the experimental
arm (p = 0.018); PFS and OS were superior in the ex-
perimental arm as well. The authors concluded that
prospective selection of first-line treatment accord-
ing to TYMS-3’UTR and ERCC1-118 polymorphisms
should be taken into account in order to increase the
probability of R0 surgery.
Take home message
Parenchymal sparing resections should be performed
for solitary, small colorectal liver metastases. In case
of unresectable metastases high conversion rates can
be achieved by using chemotherapy triplets such
as FOLFIRINOX or FOLFOXIRI with either cetux-
imab or bevacizumab. Pharmacogenetic selection of
chemotherapy may additionally improve outcomes in
this group of patients.
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